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Cancer is the second leading cause of death in the United States behind heart 
disease, killing ~600,000 Americans per year. Technological advances have lowered 
the cost of sequencing a tumor genome even faster than would have been predicted by 
Moore’s law. However, specialized computational techniques are required to 
effectively analyze this genomic data. In this dissertation, we present two such 
computational approaches to address key challenges in the field of computational 
cancer biology. Given the importance of reproducibility in biomedical research, we 
provide publicly available workflows for reproducing the results from our 
computational approaches.  
In the first part of this thesis, we present a novel approach for the extraction of 
mutation signatures from matrices of somatic mutations. One computational 
  
challenge for extracting mutation signatures is the relatively small number of 
mutations in each tumor compared to the relatively large number of distinct 
signatures, which can be mathematically similar to each other. To help address this 
computational challenge, we apply ideas from the field of topic modeling to develop 
the first mutation signature model, the Tumor Covariate Signature Model (TCSM), 
that can incorporate known tumor covariates. We focus on two mathematically 
similar signatures associated with distinct covariates to evaluate TCSM and show that 
by leveraging these covariates, TCSM can more accurately distinguish between 
mutations attributed to these two signatures than existing NMF-based approaches.  
The second part focuses on the microbes in the tumor microenvironment. It is 
not currently known whether microbial reads identified from tumor sequencing 
datasets result from contamination or represent either extracellular or intracellular 
microbial residents of the tumor microenvironment. We develop a computational 
approach named CSI-Microbes (computational identification of Cell type Specific 
Intracellular Microbes) that mines single-cell RNA sequencing (scRNA-seq) datasets 
to distinguish cell-type specific intracellular microbes from other microbes. We show 
that CSI-Microbes can identify previously reported intracellular microbes from both 
human-designed and cancer scRNA-seq datasets. Finally, we apply CSI-Microbes to 
a large scRNA-seq lung cancer dataset and identify microbial taxa in tumor cells with 
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Chapter 1: Introduction 
1.1 Background 
The rise of next-generation sequencing (NGS) has revolutionized the entire 
field of biology including cancer genomics1,2. NGS is massively parallel, high-
throughput DNA and RNA sequencing. The advent of NGS is largely responsible for 
the dramatic decrease from ~$2.7 billion and ~10 years to sequence the first human 
genome in 2001 to ~$1,000 and a few days to sequence a genome today, which 
significantly outpaces even Moore’s law3.  
At a high level, NGS starts with either DNA or RNA as input material and 
outputs thousands to millions of “short reads” where each read is a string of ~50-250 
characters from an alphabet of four characters, each of which represent one type of 
nucleotide (adenine (“A”), thymine (“T”), guanine (“G”) and cytosine (“C”)). Next, 
these short sequences are either “assembled” into a set of long contiguous regions 
(usually representing a genome)4 or “aligned” to an existing reference genome5–7. 
Read alignment is generally solved using variants on string matching algorithms from 
computer science8. In string matching terms, the read alignment problem is the 
identification of exact or near-exact occurrences of pattern R within text G where R 
represents the short DNA or RNA read and G represents the large genome. 
NGS applied to DNA is called DNA-sequencing and at a high level, can be 
partitioned into targeted sequencing, which is most commonly targeted to the exome, 
which is the ~2% of the genome that encodes proteins (whole exome sequencing or 





of DNA-sequencing is to identify mutations, which are differences between the 
genome or exome being sequenced and a reference genome, using mutation calling 
algorithms such as VarScan 210,11 and MuTect212. Mutations can broadly be divided 
into germline, which are passed down from parent to child, and somatic, which occur 
during the lifetime of an individual in a single cell and are only passed down to 
daughter cells. In cancer genomics, the objective is to identify somatic mutations that 
occur in the cancerous cells.  
NGS applied to RNA is called RNA-sequencing and is most commonly 
targeted to the messenger RNA (mRNA) molecules, which represent the intermediate 
stage between DNA and protein13. The primary objective of RNA-sequencing is to 
quantify the number of transcripts being transcribed from a given gene using 
algorithms that align reads to the transcriptome6. One challenge for analyzing DNA 
and RNA-sequencing from tumor samples is that tumor samples contain a mix of 
tumor and non-tumor cells and reads from both of these cell populations are 
intermixed in the DNA and RNA-sequencing output14. To avoid this problem of 
mixing multiple cell-types, techniques have been developed to sequence the RNA15 or 
the DNA16 of a single cell. Very recent technological advances have scaled the 
number of single cells able to be sequenced in a single experiment from one in 2009 
to tens of thousands today17. 
By time that I started my PhD in 2016, algorithmic development paired with 
the application of NGS to tens of thousands of cancer genomes by international 
consortiums such as The Cancer Genome Atlas (TCGA)18–20 and the International 





about the drivers and hallmarks of cancer14. For example, large sequencing datasets 
has enabled the identification of recurrently mutated genes in specific cancer types in 
unexpected pathways like splicing and protein homeostasis22,23. One unexpected 
finding is that while there are only a small number of genes that are frequently 
mutated across many tumors, there are a large number of genes that are infrequently 
mutated14. 
Some of these somatic mutations drive the cancer by either transforming one 
class of proteins (oncogenes) into hyperactive versions of themselves that cause the 
cell to grow uncontrollably or by transforming another type of proteins (tumor 
suppressors) into non-functional versions of themselves, which are no longer able to 
stop the cell from growing uncontrollably14. However, these somatic mutations can 
also be recognized as foreign by the immune system, which has been exploited by the 
field of cancer immunotherapy that I will mention later in this introduction. One 
prominent computational research area has been the development of computational 
tools to distinguish the small number of somatic mutations that “drive” the cancer 
(“driver mutations”) from the many somatic mutations that do not play a functional 
role in the development or progression of cancer (“passenger mutations”). One group 
of tools looks for single genes that are more mutated than expected given the 
background rate of mutation24,25. Another set of computational tools like CoMEt26 
and HotNet227 looks for sets of driver genes using mutual exclusivity or network 
propagation approaches. While these “passenger mutations” do not drive the cancer, 





became interested in mutational processes after taking Max Leiserson’s class on 
Machine Learning for Cancer Mutations in the fall of 2017. 
 
1.2 Mutational Processes in Cancer 
Somatic mutations are caused by either mutagenic processes such as 
ultraviolet radiation and smoking or defective DNA repair processes such as 
mismatch repair and homologous recombination28. Generally, the somatic mutations 
in a tumor are thought to occur from multiple co-occurring mutagenic processes29. 
For example, an inactivating somatic mutation in a gene in a DNA repair pathway can 
inactivate that pathway, which can cause additional mutations. The inactivation of the 
homologous recombination repair (HR) pathway is one of the most clinically relevant 
DNA repair pathway defects because tumors with defects in this pathway are 
particularly susceptible to treatment with PARP inhibitors30. The biallelic inactivation 
of either BRCA1 or BRCA2 is one of the most common defects to the HR pathway 
although defective HR pathway has been reported in the absence of these 
inactivation31. 
It has long been recognized that some of these mutagenic processes cause 
specific patterns of mutations such as the dramatic increase in the number of G to T 
substitutions in lung tumors of smokers compared to those of non-smokers32. 
Incredibly, Alexandrov et al.33 showed that the application of unsupervised machine 
learning approaches to thousands of cancer exomes and genomes sequenced by 
TCGA could extract mathematical patterns of mutations termed “mutation 





known mutagenic processes. In their approach, the catalog of single-base 
substitutions, which are a subset of all somatic mutations, from a tumor are first 
categorized into 96 categories, where a category is defined by the base substitute and 
the immediately flanking nucleotides (ex. C[G>T]C represents a T substituted for a G 
flanked on either side by a C). Next, each set of 96 categories from patients are 
concatenated together into a mutation count matrix of size N-by-96 where N equals 
the number of patients. Finally, this mutation count matrix is deconvolved using the 
machine learning approach non-negative matrix factorization (NMF) into two smaller 
matrices, one matrix representing the identified mutation signatures and one matrix 
representing each patient’s exposure to each mutation signature (Figure 1). 
Shiraishi et al.34 first observed that this problem could also be solved using 
machine learning approaches from the field topic modeling, which tries to identify 
topics present across a large cohort of text documents. In this analogy, the cancer 
genomes are documents, mutation signatures are topics, exposures are topic 
prevalence and mutation categories are words. The field of topic modeling has 
generated a significant number of new models and extensions to the original latent 
Dirichlet allocation (LDA)35 including correlated topic models36 as well as 
supervised37 and semi-supervised38 models. We and others34,39 have utilized the 
connection between the two fields to apply models originally developed for topic 







Figure 1: Overview of mutation signature extraction  
M, the mutation count matrix (orange) is deconvolved into two smaller matrices: P, which 
represents the mutation signatures (green) and E, which represents the exposures of each 
mutation signature in each of the N samples (blue). 
 
1.3 Tumor Covariate Signature Model 
Research goal: develop a mutation signature model that incorporates tumor 
covariates and better distinguishes between mathematically similar mutation 
signatures. 
We were particularly interested in applying semi-supervised topic modeling 
approaches to the problem of mutation signature extracting because we noticed that 
the existing unsupervised NMF-based approaches struggled to distinguish between 
mutations caused by mathematically similar mutation signatures. This problem was 
particularly pronounced when using the much smaller number of mutations called 
from whole exome sequencing (WXS), where only ~2% (the protein coding region) 
of the genome is sequenced9. We were particularly interested in this problem because 
signature 3, which has been proposed as a biomarker for PARP inhibitors because it 
is associated with defects in the aforementioned HR pathway, is mathematically very 
similar to signature 540. To address this problem, we introduce the Tumor Covariate 





incorporate known tumor metadata and demonstrate the improved performance of our 
approach in distinguishing between similar signatures on simulated and real data41. 
1.4 Transition to Cancer Immunotherapy 
During my PhD, my co-advisor, Eytan Ruppin, moved from the University of 
Maryland to the National Cancer Institute to start the Cancer Data Science Laboratory 
(CDSL). As a member of the CDSL, I began a small collaboration with the lab of 
Nick Restifo in the Surgery Branch. The Surgery Branch is one of the pioneers in the 
development of cancer immunotherapy, which uses the patient’s own immune system 
to attack their cancer42.  
During this collaboration, Nick invited me to attend the Surgery Branch’s 
clinical rounds where I met several cancer patients who were being treated by one of 
their clinical trials. After this experience, when Nick offered me a position in his lab, 
I immediately accepted even though it meant moving to a completely new area of 
research and leaving the field of mutation signatures without completing the multiple 
ideas and extensions that Max and I had planned to do after the publication of TCSM. 
Although Nick Restifo unfortunately left the Surgery Branch only a few 
months after I joined, I was already committed to the work being done there and 
continued to attend both clinical rounds and their lab meetings and journal clubs. It 






1.5 The Tumor Microbiome 
The human microbiome is the collection of microbes, which includes bacteria 
and viruses, throughout the human body43. It has been estimated that the human body 
contains roughly the same number of microbial cells as human cells44. Early studies 
of the human microbiome relied on the study of microbes that were cultured from 
human tissue and waste45. However, this culturing-based approach is limited because 
it can only be used to study microbes capable of growing in the provided culture 
media45. In contrast, NGS is able to provide an unbiased sampling of the genomic 
sequences of the microbes present in a sample43. Very recently, interest has grown in 
the tumor microbiome, which is the collection of microbes present in the tumor 
microenvironment46. Several recent papers have pointed to the functional importance 
of the tumor microbiome in both progression and response to treatment of tumors47–
49. The tumor microbiome has previously been studied computationally from NGS 
using a “computational transcriptome subtraction” approach where sequencing reads 
are first aligned to the human reference genome and unmapped, high-quality reads are 
subsequently aligned against a large database of many microbial genomes50,51. This 
approach led to the landmark discovery that the clonal integration of a previously 
unknown polyomavirus (Merkel polyomavirus) causes ~80% of Merkel cell 
carcinomas, which is a rare but aggressive human skin cancer52. Similar 
computational approaches have been applied to identify the enrichment of the 






The journal club paper that piqued my interest in the tumor microbiome 
followed up on these papers and showed that Fusobacterium can exist intracellularly 
within colorectal carcinoma cells47. The existence of Fusobacterium within these 
tumor cells meant that peptides from this bacterium, similar to peptides derived from 
mutated proteins, should be presented by the tumor cells and recognized as foreign by 
the immune system. To both my collaborators in the Surgery Branch and myself, this 
meant that we could target this bacterium (using immune cells) and treat patients with 
colorectal carcinomas.  
From a computational perspective, moving from mutation signatures to the 
tumor microbiome meant working with significantly larger datasets. Although the 
mutation count matrix input to mutation signature extraction is derived from NGS 
data, the identification of somatic mutations from NGS data is usually the primary 
outcome of sequencing, and mutation calling is always performed by the original 
authors. The main pre-processing step for mutation signature extraction is the 
conversion of the mutation calls from VCF files (average VCF file size ~ 10 
megabytes) to the mutation count matrix. The development of a Snakemake pipeline 
to apply the same standardized approach to tens of datasets with Max and a very 
talented undergraduate student Mark Keller was one of my contributions to the 
Leiserson Research Group. In contrast, the sequencing of microbial reads is usually 
an accidental by-product of sequencing to identify mutations or characterize the 
transcriptome and these microbial reads are usually ignored or filtered out by the 





needs to start with the raw reads in FASTQ format (average FASTQ file size ~10 
gigabytes), which are ~3 orders of magnitude larger.  
My first project in this field was the application of an existing computational 
host subtraction approach54 to hundreds of tumor samples from patients treated by the 
Surgery Branch to identify the subset of tumors with reads that mapped to 
Fusobacterium. I completed this analysis and provided the list of tumors to my 
collaborators in the Surgery Branch, who plan to look for immune cells that recognize 
Fusobacterium in these tumors. At the same time, Eytan pushed me to look for 
additional intracellular bacteria in these tumor samples. However, no definitive list of 
intracellular microbes existed at the time because research is biased towards a small 
number of disease-causing bacteria, which excludes most members of the human 
microbiome, and the distinction between obligate intracellular bacteria, which can 
only reproduce inside of a host cell, and facultative intracellular bacteria, which can 
reproduce both inside and outside of a host cell is blurry (personal correspondence 
with Norma Andrews). Given this background, we began to brainstorm a 
computational approach for the identification of intracellular bacteria.  
1.6 CSI-Microbes 
Research goal: develop a computational model to distinguish intracellular microbes 
from extracellular and contaminating microbes. 
To identify intracellular microbes from NGS, it is necessary to distinguish 
them from both extracellular microbes, which are microbes living outside of host 
cells, and contaminating microbes, which are microbes not originally present in the 





to remove contaminating microbes rely on the idea that samples that are processed 
together should have similar contaminates57,58. However, such approaches usually 
rely on one or at most two NGS samples per patient. In contrast, CSI-Microbes uses 
single cell RNA-sequencing, which sequences hundreds to thousands of cells from 
multiple cell-types per patient. We compare the (normalized) number of microbial 
reads between cells from different cell-types under the assumption that the levels of 
contaminating and extracellular microbes should be similar across cell-types because 
these cells are processed identically. In contrast, microbes that are enriched in one 
cell-type compared to the others likely represent intracellular microbes that reside 
within that cell-type. We demonstrate that our approach works using both human-
designed benchmark scRNA-seq datasets and cancer scRNA-seq datasets with 
previously reported intracellular microbes. Finally, we apply our approach to a large, 
recently published scRNA-seq dataset from lung cancer and identify four tumors 
where microbial taxa are enriched compared to immune cells. By comparing the 
transcriptomes of infected and uninfected tumor cells, we identify antimicrobial 
peptides such as S100A9 and multiple immune response pathways including antigen 
processing and presentation to be significantly downregulated in these infected tumor 










Chapter 2: Modeling mutation signatures using clinical and 
molecular covariates 
2.1 Preface 
In this project, we develop an approach to flexibly incorporate tumor metadata 
into the mutation signature model and demonstrate that our approach can better 
distinguish between mutations caused by similar signatures. We focus on the problem 
of distinguishing between similar mutation signatures for two reasons. First, there is a 
well-established connection between topic modeling and mutation signature 
extraction from which we are able to borrow techniques. Second, there are important 
implications for precision medicine: mutation signature 3 has been proposed as a 
biomarker for PARP inhibitors but it can be difficult to distinguish mutation signature 
3 from the similar mutation signature 5 using existing approaches. 
A manuscript describing this project was accepted to the 2019 conference on 
Intelligent Systems for Molecular Biology (ISMB) in Basal, Switzerland where I 
presented this work. The manuscript was subsequently published in the journal 
Bioinformatics as part of the conference proceedings41. The approach and the design 
of the experiments in this project were conceived jointly by my co-advisor, Max 
Leiserson, and me. I wrote the code to perform all the experiments and analyze the 
results with help processing the TCGA datasets from Mark Keller. With the exception 
of Figure 2, which was generated with help from Mark Keller and Jason Fan, I 






Somatic mutations accumulate over time in normal and cancer cells as a consequence 
of multiple mutational processes. Measuring and understanding the activity of these 
mutational process within and across tumors has important applications in modeling 
tumorigenesis, personalized cancer therapy, early detection, and prevention. The large 
cancer sequencing datasets generated over the past decade have led to the discovery 
of signatures of mutational processes present in patterns of single base substitutions28. 
Discovering and characterizing these mutation signatures and their underlying 
etiology has thus become an important challenge in the field.  
The sources of somatic mutations can be broadly classified as due to errors in 
DNA replication or from environmental or lifestyle exposures59. Errors in DNA 
replication result both from processes active in healthy cells (e.g., due to spontaneous 
deamination or reactive oxygen species) and from perturbed DNA damage repair 
pathways60. Clinicians use measures of DNA damage repair deficiency for multiple 
types of cancer therapy, including chemotherapy, synthetic lethal therapy, and, more 
recently, checkpoint inhibitor immunotherapy30,61,62. A recent study evaluated 
mutation signatures of homologous recombination repair deficiency in breast cancer 
as a predictive biomarker, and found that the mutation signature-based approach 
would significantly expand the population of patients eligible for PARP inhibitors63. 
Mutations also result from environmental or lifestyle exposures, including UV 






Mutation signatures of these exogenous processes have recently been shown 
to be prognostic in cutaneous melanomas, and revealed pre-cancerous neoplasms 
resulting from aflatoxin B1 exposure66,67. More generally, these sources of somatic 
mutations can be thought of as tumor-level covariates where for a given covariate 
(e.g., smoking status), each tumor is annotated with a specific value (e.g., smoker or 
non-smoker). 
The most widely used methods for discovering mutation signatures are based 
on non-negative matrix factorization (NMF) of a mutation count matrix33. To identify 
signatures in a cohort of N tumors, single base substitutions are first grouped into 96 
categories (based on the substitution and its surrounding 5' and 3' contexts), yielding 
an N-by-96 matrix M of mutation counts. Then, NMF is applied to decompose M into 
a N-by-K exposures matrix E and a K-by-96 signatures matrix P, and E and P are 
rescaled so that the rows of P sum to one. Each entry Ei,j is interpreted as the number 
of mutations in tumor i generated by signature j, and Pk,j is the probability signature k 
generates a mutation of category j. Alexandrov et al. applied this model to >7000 
tumors from 30 different cancer types to identify 20 mutation signatures28. 
Alexandrov and colleagues have since expanded the set to include 30 validated 
signatures that are widely studied and available from the Catalogue of Somatic 
Mutations in Cancer (COSMIC)68. 
Since Alexandrov et al. first applied NMF to identify mutation signatures, 
researchers have developed additional NMF algorithms, and addressed the problem of 
inferring exposures in a cohort given a set of active signatures. Kasar et al. introduced 





automatically learns its rank K69. Fischer et al. and Rosales et al. both introduced 
algorithms for NMF that assume that the mutation counts are drawn from a Poisson 
distribution parameterized by multiplying factors with a Gamma prior70,71. Rosenthal 
et al. introduced several heuristics for computing the exposure matrix E given a 
signature matrix P, and Huang et al. extended this work to solve the problem 
optimally72,73. 
A handful of researchers have also considered a second type of approaches to 
inferring mutation signatures that leverages lessons from the natural language 
processing problem of topic modeling. Given a corpus of observed documents, each 
drawn from the same vocabulary, the goal of topic modeling is to infer latent topics 
(distributions over words) and to assign each word in each document to its underlying 
topic74. Most topic modeling approaches such as the standard latent Dirichlet 
allocation (LDA) introduced by Blei et al. are Bayesian and make the ``bag-of-words'' 
assumption that each word in a document is independent given its underlying topic35. 
Applying topic modeling to mutation signatures means interpreting tumors as 
documents, signatures as topics, and mutation categories as the vocabulary. Shiraishi 
et al. introduced the pmsignatures method that generalizes LDA to enable mutation 
categorizations that include more than one flanking base34. Funnell et al. used a 
multi-modal topic modeling approach to simultaneously analyze patterns in single 
base substitutions and structural variations in breast and ovarian cancers39. 
Despite this methodological progress, about half of the 30 validated COSMIC 
signatures have no known etiology. The current approach to mapping signatures to 





signature exposure and a clinical/demographic features (e.g., a history of smoking and 
COSMIC Signature 4) or molecular features (e.g., BRCA1 inactivations and COSMIC 
Signature 3)75,76. Further, even for two signatures with known etiologies, it can be 
challenging to distinguish their respective exposures with existing methods if the 
signatures are similar. For example, COSMIC Signature 3 and Signature 5 are highly 
similar (cosine similarity of 0.83), but Signature 3 is associated with homologous 
recombination repair deficiency and Signature 5 is associated with age at diagnosis 
and genetic mutations in the nucleotide excision repair pathway40,76–78. 
We hypothesize that to overcome these challenges, methods for modeling 
mutation signatures and tumor-level clinical or molecular covariates are needed. To 
begin to address this challenge, we present the Tumor Covariate Signature Model 
(TCSM) to learn how observed tumor-level covariates change signature exposure. We 
show on simulated and real mutation datasets that, by modeling tumor-level 
covariates, TCSM outperforms existing NMF- and topic modeling-based approaches 
that are limited to using only a tumor's mutations as input. We find that the largest 
differences in performance come when inferring exposures of held-out tumors not 
used to infer signatures, and that these differences lead to improved performance in 
downstream analyses, including predicting DNA damage repair deficiency. TCSM is 
the first method to model mutation signatures and their tumor-level covariates in 






2.3.1 Tumor Covariate Signature Model (TCSM) 
We present a probabilistic model of mutation signatures and their covariates 
that builds off of the well-studied area of topic modeling and the previously observed 
connection between topic modeling and mutation signatures34,35,39,74. Topic models 
are generative models for text data, and usually encode the “bag-of-words” 
assumption that words are independent given their underlying topics. The observed 
data for topic models are N documents w, where each document wi consists of ni 
words from vocabulary V such that wij ∈ V,1 ≤ j ≤ ni. Topic modeling seeks to 
uncover (1) K global latent variables βk called topics, where each topic is a probability 
distribution over the vocabulary; and, (2) local latent variables including the K topic 
mixing proportions θi per document, and the assignment zij ∈ {1,...,K} of each 
observed word wij to a topic. The most common topic modeling approaches such as 
latent Dirichlet allocation (LDA) by Blei et al.35 are Bayesian, where both βk and θi 
are multinomial distributions with Dirichlet priors. 
In order to model mutational processes in cancer, we interpret tumors as 
documents, mutation categories as the vocabulary, signatures as topics, and signature 
exposures as topic mixings. Following earlier work, we categorize mutations into L = 
96 mutation categories based on its base substitution (C:G>A:T, C:G>G:C, C:G>T:A, 
T:A>A:T, T:A>C:G, T:A>G:C) and the 5’ and 3’ flanking bases (four choices each) 
in the reference genome. 
We present TCSM to allow observed tumor covariates to change the per tumor 





modeling using document-level covariates, to our knowledge, this is the first time this 
work has been connected to mutation signatures37,38,79. Importantly, we do not model 
the generative process of the observed covariates, but instead take a conditional 
approach where the D observed covariates ~xi of the ith tumor change the prior 
distribution over the signature exposures θi. For example, an observed covariate could 
be a binary indicator for biallelic inactivation of a DNA damage repair gene. The 
model is flexible enough that the covariates can be any real valued number. The first 
element of ~x is always set to 1 to model the mean exposure of each signature. 
More specifically, we follow the “topic prevalence” approach of the Structural 
Topic Model from Roberts et al. that combines Dirichlet-multinomial regression and 
the correlated topic model, and describe the model as it relates to mutation 
signatures36,38,79,80. The correlated topic model places a logistic normal prior on θ 
such that signature exposures can co-vary (correlate) and was previously used to 
analyze mutation signatures in breast cancer by Funnel et al.39 The mean of the 
logistic normal is set for tumor i as x~iΓ, where Γ is a D×(K−1) matrix of exposure-
covariate coefficients. The full generative process for the TCSM for tumor sample i 
with ni mutations is as follows: 
θi ∼ LogisticNormal(~xiΓ,Σ), (1) zij ∼ Multinomial(θi), 1 ≤ j ≤ ni, (2) wij ∼ 
Multinomial(βzij), 1 ≤ j ≤ ni. (3) 
We place a hyperprior on the exposure-covariate coefficients Γ = [γ1;...;γK−1] where 
 γd,k ∼ Normal(0,σk2), 1 ≤ d ≤ D,1 ≤ k ≤ K − 1, 







Figure 2: Overview of the Tumor Covariate Signature Model (TCSM)  
We show an illustrative example of d=1 covariate and K=3 signatures. Given the observed 
mutations in a cohort of patients (top left), TCSM learns per patient exposures and 
assignments (top right), and a global set of signatures and covariate-exposure coefficients 
(bottom right). The associations between covariates and exposures are then tested for 
statistical significance (bottom left). Parts of the design of the figure are inspired by Blei et 
al. and Alexandrov et al.33,74 
 
2.3.2 Model training and hyperparameter selection 
We train the TCSM to learn the signatures β, signature exposures θ and 
covariance Σ, and exposure-covariate coefficients Γ using the variational expectation-
maximization algorithm from Roberts et al. and their recommended initialization 
procedure80. The latter is based on a spectral decomposition (via non-negative matrix 
factorization) of the L × L mutation co-occurrence matrix that was shown to lead to 
quicker convergence of topic models80. 
The main hyperparameter of TCSM is the number K of signatures. We set K 
empirically through 5-fold cross-validation, completely holding out 20% of the 
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tumors in one fold. We use the “document completion” approach of Wallach et al. to 
compute the likelihood of all of a held-out tumors’s mutations wtest i.e., computing 
Pr(wtest|β,·), where · represents hyperparameters81. We choose the K when the 
likelihood plateaus. 
Learning exposures in held-out samples. When the signatures β are given (e.g. 
from learning on a training cohort), we learn the exposures θ for additional, held-out 
samples by maximum a-posteriori probability (MAP) estimation. 
2.3.3 Imputing binary covariates in held-out samples 
One advantage of TCSM is that it enables probabilistic imputation of held out 
(or missing) covariates, including for previously unseen tumors. For example, for a 
single binary covariate in tumor xid, we compute the loglikelihood ratio (LLR) of the 
tumor’s mutations under the model with xid = 1 and xid = 0: 
                           Pr(w|xi1=1,β,Σ,Γ,·) 
 LLR = log   , (5) 
                           Pr(w|xi1=0,β,Σ,Γ,·) 
where · is the hyperparameters of the model. A positive LLR indicates that the 
tumor’s mutations are better fit when xid = 1. After imputing held-out or missing 
covariates in this way, we then report the exposures θ estimated from the model with 
higher likelihood for downstream analysis. 
2.3.4 Statistical Significance of covariates on signature exposure 
After applying variational EM to infer the latent variables of TCSM, we 





exposure. In this work, we only perform the test for a single binary covariate. For 
each signature k and binary covariate d, we generate 10,000 random exposures to 
signature k, half setting xd = 1 and half setting xd = 0, according to Equation 1. We 
then generate an empirical distribution by repeating these steps for TCSM trained on 
data where the covariates are permuted among samples uniformly at random. We 
compute a P-value for a signature-covariate pair by counting how often the mean 
differences in exposure of any signature-covariate pairs on the permuted datasets are 
greater than the mean difference of exposures on real data. We specifically test for an 
increase in exposure and only report the cases where the mean exposure when the 
covariate is present is greater than the mean exposure without the covariate; the 
parameterization of the Dirichlet (or Logistic Normal approximation) necessarily 
means that increasing the exposure of one signature will decrease the exposure of at 
least one of the others. We report Benjamini Hochberg-corrected P-values82. 
2.3.5 Benchmarking of mutation signature methods 
It is challenging to compare mutation signature methods on real data because 
the true signatures and exposures are unknown. For that reason, we perform 
comparisons on both simulated and real data. 
 
2.3.5.1 Simulated mutation datasets 
 
We generate simulated mutation datasets from a simplified version of TCSM 
with known ground truth parameters and hyperparameters based on real cancer 
datasets and previous mutation signatures studies. The simulation process is 





instead sample each tumor’s exposures θ from a Dirichlet (as in Dirichlet-
multinomial regression) instead of the logistic normal38. As a case study, we generate 
data to reflect homologous recombination (HR) repair deficiency in breast cancer, 
using a single binary covariate. We use four of the validated COSMIC signatures 
found to be active in breast cancer (Signatures 1, 2, 3 and 5)68. For each sample, we 
generate a single binary covariate xi, representing HR deficiency, that increases the 
prior probability of exposure to Signature 3 (the COSMIC HR deficiency signature). 
We then generate θi of tumor i from a Dirichlet distribution with parameter vector ηik 
= exp{λ0,k + λ1,kxi}. We use λ0 = [−2,−2,−5,−2] and λ1 = [0,0,4,0]. Thus, simulated 
tumors with HR deficiency have a much greater prior probability of high Signature 3 
exposure, while the other signatures prior probabilities remain unchanged. We note 
that Signatures 3 and 5 have a high cosine similarity of 0.83 to each other, making it 
challenging to distinguish between Signature 3 mutations resulting from HR 
deficiency and Signature 5 mutations. 
2.3.5.2 Evaluation methods 
 
To quantify the importance of tumor covariates in modeling mutation 
signatures, we compare the TCSM with and without covariates. We also compare the 
models to non-negative matrix factorization, using the popular Somatic Signatures 
implementation of NMF for mutation signature analysis83. 
Recovery of ground truth parameters. On simulated data, we compare the 
models on their learned signatures (using average cosine similarity) and exposures 





Held-out log-likelihood. We compare TCSM with and without covariates 
using average log-likelihood per mutation of held-out data. Since NMF is non-
probabilistic, we cannot compare it to TCSM using likelihood. 
Prediction tasks using estimated exposures. To compare between probabilistic 
and non-probabilistic models, we compare the prediction power of the inferred 
exposures for a target binary covariate that is known to be associated with mutation 
signatures. First, we learn the mutation signature model on the training data set. Then, 
we use the model to estimate the exposures of the test data set to the identified 
signatures. Importantly, while the covariate is used when training TCSM, we hold it 
out completely in the testing dataset. For TCSM, we first impute the covariate in 
held-out samples before computing exposures (as described in Section 2.3.2). For 
NMF, we estimate the exposures in held-out samples using SignatureEstimation72. 
Next, a Support Vector Classification (SVC) model with a linear kernel is trained 
using the normalized exposures of the training dataset and the target covariate and 
evaluated on the test dataset. When the distribution of the target covariate is 
unbalanced, we set the class weight parameter of the SVC method to balanced and 
evaluate the performance using area under the precision-recall curve (AUPRC). 
2.3.6 Implementation and software 
We implemented TCSM in Python 3. We perform model training and 
inference using a wrapper of the Structural Topic Models R package79. We provide a 
workflow for reproducing the experiments in the paper using Snakemake84. The 






We analyze mutations in breast cancer exomes processed and standardized by 
The Cancer Genome Atlas PanCanAtlas and downloaded from the Genomic Data 
Commons85. To investigate the relationship between breast cancer and homologous 
recombination (HR) repair deficiency, we restrict our analysis to 760 tumors with 
called biallelic inactivation of 82 genes in the HR pathway and counts of LST (Large-
scale State Transitions; a measure of HR deficiency) from Riaz et al.31,86. We obtain 
biallelic inactivation calls for the 82 HR genes by combining epigenetic silencing 
calls from Knijnenburg et al. with germline and somatic mutation and loss of 
heterozygosity (LOH) calls from Riaz et al.31,87. 
We also analyze 466 melanoma exomes and 485 lung squamous cell 
carcinoma tumors from The Cancer Genome Atlas PanCanAtlas dataset85. We 
exclude 48 melanoma samples that were annotated as either acral melanomas or 
metastatic samples with unknown primary tumor origin by 66 (list of excluded 
samples obtained via personal correspondence). We download CC>TT dinucleotide 
polymorphism counts for these samples from both Firehose and Alexandrov et al.88 
We combine these data sources by taking the average CC→TT count for samples that 
appear in both sources. 
2.4 Results 
2.4.1 Comparison on simulated data 
We first compare the Tumor Covariate Signatures Model (TCSM) on 





factorization (NMF) and TCSM using no covariates. To better understand how a 
single signature with changes in exposure due to tumor covariates affects the 
performance of TCSM and existing methods, we perform this comparison using 
simple simulated datasets with a single binary covariate that changes the prior 
probability of exposure for a single signature. The remaining parameters are set using 
previously discovered mutation signatures or are derived from real mutation datasets. 
We randomly generate fifty simulated datasets (see Section 2.3.5), varying the 
number of samples from 50 to 250 and sampling with replacement the number of 
mutations per sample from real breast cancer exomes from The Cancer Genome Atlas 
PanCanAtlas dataset85. We then compare the output of our model to NMF as 
implemented by the SomaticSignatures R package83. We apply TCSM with and 
without covariates to directly quantify the importance of incorporating tumor 
covariates. We evaluate the models in terms of the log-likelihood of held-out samples 
for K = 2−8. We compute the average held-out log-likelihood using Monte Carlo 
cross-validation with fifty train/test splits, holding out 20% of the samples. We also 
report each model’s in-sample accuracy at identifying the hidden signature and 
exposure parameters. 
In terms of model selection (identifying the true K), we find that TCSM with 
covariates consistently outperforms TCSM without covariates and SomaticSignatures. 
While none of the models are able to consistently learn the true number of signatures 
(K = 4) in datasets with only 50 samples, TCSM identifies the true K more often than 
the other methods (7/50 times compared to 2 and 1 for TCSM without covariates and 





variances for model selection for SomaticSignatures, as suggested by the authors83. 
When we use 250 samples, we find that TCSM with covariates identifies the true 
number of signatures (K = 4) for 35 of the datasets (compared to 3 and 19 for TCSM 
without covariates and SomaticSignatures, respectively). We also find that covariates 
provide additional signal, as TCSM with covariates achieves higher held-out 
likelihood than the TCSM without covariates on the majority of the synthetic datasets 
when K = 4 for N = 50 (28/50) and nearly all datasets when N = 250 (49/50). All 
models identified the signatures with relatively high accuracy (cosine similarity 
>0.90; Figure 3A) for N > 100. However, TCSM with covariates was better able to 
distinguish between mutations caused by Signatures 3 and mutations caused by 
Signature 5, with higher accuracy in identifying the true exposures across all datasets 
(Figure 3B). 
 
Figure 3: Benchmark of TCSM on simulated data  
TCSM with (red) and without (blue) covariates is compared to the NMF-based 
SomaticSignatures (green) on synthetic data. (A) Cosine similarity of inferred signatures (β) 
to hidden Signatures 3 and 5 using the true K = 4 averaged across fifty datasets, varying the 
number of samples. (B) Mean-squared error of the inferred exposures (θ) for the same 
datasets as in (A) 
2.4.2 Homologous recombination repair (HR) deficiency in breast cancer 
After establishing the utility of our model on simulated data, we turn to test it 
on real data. As an initial case study, we apply TCSM to study homologous 





in breast cancer is particularly important because of the clinical importance of 
identifying patients who might respond to PARP inhibitors30. We use the TCGA 
BRCA cohort and divide the samples stratified by the biallelic HR covariate 
(described below) into (1) a training/validation data set (75%) for choosing the 
encoding of the covariate, model selection, and benchmarking TCSM with/without 
covariates; and (2) a completely held-out test dataset (25%) for evaluation with a 
prediction task. 
2.4.2.1 Covariate selection 
The first key challenge in applying TCSM to real data is choosing the events 
or measures to use as covariates. Ideally, the covariates should be associated with 
changes in signature exposure and be easy to interpret biologically in order to reveal 
signature etiology. We begin by examining traditional markers of homologous 
recombination deficiency, including the biallelic inactivation of specific genes in the 
HR pathway31 and the number of large-scale state transitions (LST), which are 
chromosomal breakages that generates fragments of at least 10 Mb86. 
We first compare TCSM using LST count to TCSM using the biallelic 
inactivation of a gene in the HR pathway as covariates in terms of held-out log-
likelihood for K = 2 − 10 (Appendix A Figure 1). We encode the biallelic inactivation 
of a gene in the HR pathway as a single binary covariate where a 1 indicates the 
tumor has a biallelic inactivation in one of the seven genes (ATM, BRCA1, BRCA2, 
CHEK2, FANCM, FANCF, RAD51C) in the HR pathway inactivated in at least five 
samples in our cohort. We find that LST gives consistently better performance as 





be a direct readout of the functional status of the HR pathway. However, even though 
TCSM can use continuous variables as covariates, binary covariates – such as 
whether a gene has a biallelic inactivation – are more interpretable and easier to 
analyze downstream, e.g., when inferring the true value in a previously unseen 
sample. Therefore, we search for a subset of the HR genes whose biallelic 
inactivation maximizes the mutual information with the number of LSTs. More 
specifically, we use a greedy algorithm that adds the HR gene whose inactivation 
maximizes the mutual information with LST, halting when the mutual information 
stops increasing. The genes in the identified set, BRCA1, BRCA2 and RAD51C, 
exhibit almost perfect mutual exclusivity (1/57 tumors have co-occurring mutations), 
a pattern expected for genes in the same pathway89. Further, TCSM trained using a 
single covariate for these three genes achieves superior performance than TCSM 
trained using a single covariate for all seven genes and nearly the same performance 
as TCSM using LST count as the covariate (Appendix A Figure 1). In subsequent 
sections, we refer to TCSM with a single covariate – the biallelic inactivation of 
either BRCA1, BRCA2 or RAD51C – as TCSM with the biallelic HR covariate. 
 
2.4.2.2 Automated discovery of mutation signatures of etiology 
 
After selecting the covariate to use, we perform model selection over the 
range K = 2 − 10 using the TCSM with the biallelic HR covariate. We select K = 5 as 
that is where the held-out log-likelihood plateaus and show the resulting signatures in 
Figure S3. All five signatures have cosine similarity > .8 to COSMIC signatures with 





APOBEC signatures (COSMIC Signatures 2 and 13), TCSM Signature 2 maps to the 
HR deficiency signature (COSMIC Signature 3), TCSM Signature 3 maps to the 
polymerase epsilon signature (COSMIC Signature 10), TCSM Signature 4 maps to 
the mismatch repair (MMR) deficiency signature (COSMIC Signature 6) and TCSM 
Signature 5 maps to the aging signature (COSMIC Signature 1). Reassuringly, our 
covariate significance test identifies statistically significant increases in exposure to 
one TCSM signature, the TCSM signature that resembles COSMIC Signature 3, in 
the presence of the biallelic HR covariate (HR-proficient mean: .200, HR-deficient 
mean: .418, Benjamini-Hochberg-corrected P < .001). 
Next, we evaluate the ability of the TCSM to impute a hidden biallelic 
covariate value given a held-out tumor’s mutations. We impute each tumor’s biallelic 
covariate when it is in the test fold during 5-fold cross validation. The log-likelihood 
ratio of tumors with inactivation of known HR genes – including inactivation of one 
of the three HR genes used in training (orange) or four other HR genes (green) – is 
significantly greater than the ratio of the samples without the inactivation of known 
HR genes (blue; Figure 4C; Wilcoxon rank sum P = 7e−22). Moreover, the tumors 
predicted to be HR deficient (i.e., those with LLR > 0) without known HR 
inactivation have a significantly higher number of LSTs than the tumors predicted to 
be HR proficient (Wilcoxon rank sum P = 8e−10, Figure 4C), possibly indicating that 
they may have some form of HR deficiency due to some other event. Together, these 
results demonstrate the use of TCSM for automated discovery of mutation signatures 





2.4.2.3 Comparison to other methods 
 
We compare the performance of TCSM with the biallelic HR covariate to 
TCSM without covariates (Figure 4A) for K = 2−10. We find that using covariates 
leads to an increase in held-out log-likelihood for all K> 2. 
Next, we add NMF to the comparison. Since NMF is not probabilistic, we 
compare the estimated exposures of the three methods. We use the SomaticSignature 
R package implementation of NMF using the SomaticSignatures model selection 
process. We choose K = 5 because the model selection yields a range from K = 3 − 6 
(Appendix A Figure 4) and K = 5 enables the fairest comparison between the models. 
The five signatures extracted by SomaticSignatures map with cosine similarity > .8 to 
the same five COSMIC signatures as TCSM. 
We compare how well the estimated exposures of each method for held-out 
tumors correspond with standard measures of HR deficiency. We train a linear model 
to classify tumor HR deficiency from the tumor’s signature exposures. Davies et al. 
recently demonstrated the potential of a similar approach using NMF-based exposures 
to expand treatment with PARP inhibitors to a broader class of patients63. As ground 
truth HR deficiency, we use the biallelic inactivation of BRCA1, BRCA2 or RAD51C. 
We then train the model on exposures from TCSM with the biallelic HR covariate, 
TCSM without covariates and SomaticSignatures (see Section 2.3.5.2 for details). To 
enable a fair comparison, TCSM is not provided with the true value for the biallelic 
HR covariate for the held-out tumors but instead infers the covariate value before 





area under the precision-recall curve (AURPC) on held-out cohorts not used when 
training the classifier. 
We first compare within the cross-validation framework used for model 
selection. TCSM with the biallelic HR covariate (mean AUPRC=.62 across the 5-
folds) outperforms both TCSM without covariates (mean AUPRC=.57) and the NMF 
approach (mean AUPRC=.56). We then compare on the completely held out 25% 
samples not used for model selection or choosing the encoding for covariates. Again, 
we find that TCSM with the biallelic HR covariate (AUPRC=.64) outperforms both 
TCSM without covariates (AUPRC=.59) and the NMF approach (AUPRC=.58). 
 
 
Figure 4: Evaluation of TCSM on TCGA breast cancer data 
(A) Comparison of the log-likelihood of held-out samples across K = 2 - 10 between TCSM 
with the biallelic HR covariate (inactivation of BRCA1, BRCA2, or RAD51C) and TCSM 
without covariates. (B) The log-likelihood ratio (LLR) of samples with the biallelic HR 
covariate hidden where LLR > 0 indicates the mutations of a sample are more likely under 
the biallelic HR covariate inactivation model. (C) After excluding tumors with known 
biallelic inactivation of either BRCA1, BRCA2 or RAD51C, the plot of a tumor’s LLR against 
its LST count. 
2.4.3 Simultaneously learning signatures in melanomas and lung cancer 
Next, we investigate mutation signatures in cutaneous melanomas (SKCM) 
and lung squamous cell carcinomas (LUSC), two types of cancer where mutational 
processes relating to environmental or lifestyle exposures are predominant. We 
examine whole-exome sequences of 418 SKCM and 485 LUSC tumors from TCGA 
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PanCanAtlas (see Section 2.3.7 for details). One advantage of TCSM is the ability to 
encode cancer type in the model while performing a pan-cancer analysis. In contrast, 
previous work searched for a consensus set of signatures from a pan-cancer run and 
individual cancer type runs28,88. 
We investigate using multiple covariates for TCSM: cancer type, smoking 
history (expected for many lung cancers), and exposure to UV radiation (expected for 
many melanomas). For cancer type, we use one binary covariate for SKCM and one 
binary covariate for LUSC. For smoking history, we set to one if the patient has a 
history of smoking and zero for never-smokers. Note that smoking history data are 
missing for SKCM patients, so we set their history of smoking covariates to zero. For 
UV radiation, we use the number of CC>TT mutations in the tumor, which has long 
been known as a marker of UV radiation exposure90. Note that these dinucleotide 
mutations are excluded from the traditional 96 single base substitution categories 
analyzed by mutation signature methods and are thus not included in the 
observations. 
We first perform model selection using TCSM and compare the held-out log-
likelihood using all four covariates (cancer type, smoking history and UV radiation 
exposure), using only the cancer type and using no covariates (Figure 5A). We find 
that using the cancer type covariates results in a large improvement in held-out 
likelihood across K compared to using no covariates (Figure 5A). In contrast, we find 
that using all four covariates results in a much smaller improvement in held-out 
likelihood across K compared to using only cancer type. We hypothesize that the 





with the cancer type. To simplify downstream analysis, we remove the smoking status 
and UV radiation exposure covariates and use only the cancer type covariate. To 
further simplify the model, we use a single cancer type covariate with two possible 
values (LUSC and SKCM), instead of using one binary covariate for each cancer type 
as these two models have identical held-out likelihood performance (Appendix A 
Figure 5). Using TCSM with the single cancer type covariate, we select K = 4 as the 
optimal number of signatures and show the resulting signatures in Appendix A Figure 
7. 
The four extracted signatures resemble known COSMIC signatures (Appendix 
A Figure 6): the ultraviolet (UV) radiation-associated signature (Signature 7), the 
smoking-associated signature (COSMIC Signature 4), the APOBEC-associated 
signature (Signatures 2 and 13) and a signature that resembles both the aging-
associated signature (Signature 1) and the mismatch repair deficient signature 
(Signature 6), which is likely a composite of the two COSMIC signatures that share a 
high cosine similarity to each other (cosine similarity=.84). Reassuringly, TCSM 
finds an association between the SKCM cancer type and an increase in the exposure 
to the TCSM signature most similar to COSMIC Signature 7 (LUSC mean: .113, 
SKCM mean: .808, Benjamini Hochberg-corrected P < .001). TCSM finds an 
association between the LUSC cancer type and an increase in the smoking signature 
(LUSC mean: .448, SKCM mean: .054, Benjamini Hochberg-corrected P < .001), the 
APOBEC signature (LUSC mean: .180, SKCM mean: .013, Benjamini Hochberg-
corrected P < .001) and the mismatch repair/aging signature (LUSC mean: .260, 





We then investigate imputing a tumor’s cancer type from its mutations. 
Campbell et al. examined 660 lung adenocarcinomas (LUAD) and 484 LUSC from 
TCGA and identified three LUSC tumors whose molecular profile resembled 
melanomas91. They hypothesized that these three LUSC tumors might represent 
metastases from the skin and noted that one of these patients was previously 
diagnosed with basal cell carcinoma. Campbell et al. reported a similar result in a 
targeted sequencing dataset, such that 35% of hypermutated lung cancers had high 
COSMIC Signature 7 exposure92. Motivated by these reports, we use TCSM to 
reexamine the TCGA LUSC tumors to quantify the probability each primary tumor 
was correctly classified as LUSC. 
We find that the cancer types imputed by TCSM are the same as the classified 
cancer type in the vast majority of cases (Figure 5B). All but three LUSC have 
negative log-likelihood ratios, and the three outliers all have LLRs > 1 (indicating 
that they strongly resemble melanomas). Indeed, these three outliers are the same as 
those Campbell et al. identified as having high UV radiation signature exposure. The 
number of CC>TT mutations in these tumors further supports the hypothesis that 
they are misclassified melanomas, as they are the only three tumors in the LUSC 
cohort with at least 15 CC>TT mutations (Figure 5B). This analysis confirms and 
expands upon the conclusions of Campbell et al. and demonstrates the use of TCSM 
for probabilistically reasoning about cancer type classification. 
TCSM identifies several SKCM tumors as likely LUSC (LLR >0) that are 
less likely to be true misclassifications. One explanation is that SKCM tumors with 





compared to SKCM tumors with LLR > 0 (mean number of mutations: 70 vs. 1032, 
P = 5e−27 Wilcoxon rank sum; mean number of CC>TT mutations: 0 vs. 23, P = 
1e−27). However, many SKCM tumors with very few or no CC>TT mutations are still 
correctly classified as SKCM tumors, which demonstrates the importance of using the 
entire mutation spectrum, instead of a single feature. 
 
 
Figure 5: Evaluation of TCSM on TCGA melanoma and lung cancer samples  
(A) The held-out log-likelihood plot used for model selection to obtain K = 4. (B) The log-







mutations of the tumor are more likely under LUSC and LLR > 0 means the mutations of the 
tumor are more likely under SKCM. 
2.5 Discussion 
We presented the first probabilistic model, TCSM, of mutation signatures and 
their tumor-level clinical/demographic and molecular covariates. We found that 
TCSM outperformed NMF- and topic modeling-based approaches on both simulated 
and real mutation datasets, particularly in distinguishing between exposures of similar 
signatures. We then modeled mutation signatures of homologous recombination 
repair deficiency in breast cancers, demonstrating an approach for selecting 
interpretable covariates and predicting HR deficiency in held-out tumors. We also 
modeled mutation signatures in melanomas and lung cancers simultaneously. By 
including cancer type as a covariate, we were able to provide statistical support for 
earlier claims that three lung cancers in our cohort from The Cancer Genome Atlas 
are misdiagnosed metastatic melanomas. 
The key advantage of TCSM over existing methods is in inferring exposures, 
particularly in distinguishing exposures of similar signatures. For example, we found 
that a linear model trained on exposures from TCSM was better able to predict HR 
deficiency than linear models trained on exposures from methods that do not model 
covariates. While not the focus of the applications in this study, we hypothesize that 
by modeling the effects of tumor covariates on signature exposures, TCSM may be 
more sensitive than existing methods in discovering rare signatures. To do so may 
require explicit modeling of the number of mutations per tumor. 
While modeling tumor covariates of mutation signatures brings clear 





model. Encoding a particular covariate requires considering its sparseness and 
interpretability. Consider the covariate representing HR deficiency. We reasoned that 
the biallelic inactivation of genes in the HR pathway are more interpretable than 
existing HR indices – even if the HR indices may be a more direct encoding of the 
covariate – and that because the inactivation of each HR gene is sparse and 
approximately mutually exclusive, they could be combined into a single event. 
Selecting covariates also brings challenges, particularly when the mutational 
processes active in a cohort are not well understood, there are multiple covariates 
related to the same process, there is population structure or batch effects correlated 
with exposure, or for discovering new signatures. In this case, it may be important to 
add a covariate selection component to the model. 
Certain aspects of TCSM are computationally expensive and can be improved. 
For example, choosing the value of K, the number of signatures, requires multiple 
runs of TCSM for each potential value of K. One future extension is to model K as a 
draw from a Dirichlet Process, a version of which is popular for topic modeling93. 
Another computationally expensive step is our statistical test, which requires 
sampling 10,000 random exposures from the model because the mean of the logistic 
normal distribution is parameterized by a vector of K-1 coefficients, which does not 
lend itself to an easy interpretation of the significance of exposure-covariate 
associations. Substituting the Dirichlet distribution for the logistic normal 
distribution, such as in Mimno and McCallum38, would improve the direct 
interpretability of the parameters, which would enable a fully Bayesian approach for 





Finally, one direction we plan to explore in future work is modeling the effect 
of covariates on the signatures themselves, rather than their exposure. This is 
analogous to topic models of regional variation in language usage per topic80,94,95. 
There are multiple cases of researchers reporting multiple different signatures of the 
same mutational process, though it is not always clear what each of the distinct 
signatures represents. Learning how covariates change the signature themselves may 





Chapter 3: Identification of tumor-specific intracellular 
microbes from scRNA-seq using CSI-Microbes 
 
3.1 Preface 
In this project, we develop the first tool to identify cell-type specific 
intracellular bacteria from scRNA-seq data. We apply our tool to a large number of 
scRNA-seq datasets to identify tumor cell-specific microbes for two main reasons. 
First, it is computationally challenging to both identify microbial reads and then 
distinguish reads from contaminating microbes from those of true intracellular 
microbes, which we do by using different human cell-types as controls. Second, these 
tumor cell-specific intracellular microbes may be targeted by antibiotics or T cell-
based therapy.  
I built the pipeline and wrote the code to download the datasets, perform all 
the experiments and analyze the results. Alejandro Schäffer supervised experiments 
to improve the microbial read identification step of the pipeline and assisted in the 
administrative approval of the datasets. Fiorella Schischlik greatly assisted me in the 
generation of the figures. Eytan Ruppin supervised this project. We placed a version 
of this manuscript describing the initial version of the pipeline and the initial results 
from this project on the pre-print server bioRxiv in May, 202096. This version of the 
manuscripts reflects a significant improvement and is currently being finalized for 






Several recent papers have pointed to the functional importance of the tumor 
microbiome. For example, bacteria of the genus Fusobacterium are enriched in 
colorectal carcinoma compared to matched normal tissue, drive tumorigenesis, 
influence response to chemotherapy and bind to multiple human immune inhibitory 
receptors47–49,53,97,98. pks+ E. coli have been shown to induce a mutation signature 
frequently found in colorectal carcinoma99. In pancreatic cancer, a subset of taxa from 
the class Gammaproteobacteria were shown to mediate tumor resistance to 
chemotherapy100. A computational analysis of the unmapped reads from whole-
genome sequencing (WGS) and whole-transcriptome sequencing (RNA-seq) 
experiments across 33 tumor types from The Cancer Genome Atlas (TCGA) cohort 
identified a variety of bacterial genera present in different tumor types and 
demonstrated that after filtering out potentially contaminant species, one can 
successfully build a predictor of cancer type based on tumors’ microbial 
composition58. 
Recent papers have demonstrated that some members of the tumor 
microbiome live intracellularly in tumor and non-tumor cells within the tumor 
microenvironment. For example, the previously mentioned Fusobacterium has been 
shown to bind to ligands overexpressed by colorectal carcinoma cells; it can invade 
and exist intracellularly within these cells47,101. Another recent publication used 
multiple experimental techniques to interrogate the microbiome of seven cancer types 
and found that each cancer type has its own characteristic tumor microbiome and 





Further, it was recently reported that peptides derived from proteins in 41 bacterial 
species, including Fusobacterium nucleatum, are presented on the human leukocyte 
antigen class I and II (HLA-I and HLA-II) molecules of melanoma cells, which 
suggests that intracellular bacteria can be exploited therapeutically103. Despite these 
advances, it is challenging to identify which microbial taxa reside intracellularly and 
whether they reside exclusively or preferentially in tumor cells, immune cells or cells 
of the non-cancerous solid tissue adjacent to the solid tumor. Just recently, the study 
by Nejman et al.102, which characterized the composition of the tumor microbiomes 
using 16S ribosomal RNA104,105 and identified the intracellular localization of some 
bacteria using staining, was unable to classify which bacterial taxa resided 
intracellularly in which cell types.  
Here, we present a computational approach named CSI-Microbes 
(computational identification of Cell-type Specific Intracellular Microbes), aimed at 
identifying intracellular microbes that are cell-type specific from single cell RNA 
sequencing (scRNA-seq) datasets. Previous studies looking at microbial reads from 
scRNA-seq of host cells have generally focused on viruses106,107. The only previous 
study to analyze bacterial reads from scRNA-seq of host cells that we are aware of 
did so in the context of  known Salmonella infection using a protocol designed to 
capture bacterial reads108. CSI-Microbes extends upon this approach by 
demonstrating that viruses and intracellular bacteria that preferentially reside within 
one cell-type can be identified from two commonly used scRNA-seq protocols 
(Smart-seq2 and 10x) without knowing a priori the infecting virus or bacteria as long 





identification context it is necessary to consider all microbial reads identified from the 
datasets, many of which are likely contaminants. Using user-specified cell-type 
annotations (such as those based on host transcriptomic data), CSI-Microbes aims to 
identify microbial reads that are enriched in specific cell types. This step controls for 
contaminating and extracellular microbes, whose abundances is assumed not to vary 
significantly between cells of different types after proper normalization. Finally, we 
show that the microbial abundances of the intracellular microbes identified are likely 
to be of functional significance as they are associated with host transcriptomic 
changes. 
We first test and validate our approach using two human-designed benchmark 
datasets where human immune cells were exposed to Salmonella and both infected 
and bystander cells underwent scRNA-seq109,110. To test CSI-Microbes in cancer, we 
analyze two 10x datasets from cancer types with previously reported tumor-specific 
intracellular microbes and show that it successfully identifies both the previously 
reported enrichment of Merkel polyomavirus in Merkel cell carcinoma cells and 
Fusobacterium in colorectal carcinoma cells as well as the novel enrichment of 
Hathewaya histolytica in colorectal carcinoma cells from one patient. Subsequently, 
we apply CSI-Microbes to analyze a Smart-seq2 dataset of ~11,000 cells from 13 
lung tumors. We identify multiple bacterial taxa including the bacterial species 
Cutibacterium acnes in tumor cells of four lung tumors, the genus Leptotrichia in 
stromal cells of one lung tumor and multiple bacteria taxa in the immune cells of 
another lung tumor. Finally, we performed a differential expression analysis between 





host transcriptomic changes associated with intracellular bacteria. Notably, we find 
the gene S100A9, which encodes half of the anti-microbial heterodimer calprotectin, 
to be the most down-regulated gene in tumor cells with intracellular bacteria. At the 
pathway level, we find that pathways associated with innate immune response 
(including defense response and response to biotic stimulus), antigen processing and 
presentation and multiple cytokine response pathways are downregulated in the 
infected tumor cells. These associations both testify to the significance of the results 
of CSI-Microbes and suggest potential mechanisms for how and why intracellular 
bacteria reside within tumor cells.  
3.3 Results 
3.3.1 Overview of CSI-Microbes 
The inputs to CSI-Microbes are i) FASTQ files from scRNA-seq experiments 
and ii) cell metadata, including cell type annotations and iii) known covariates, such 
as the sequencing plate, that may be associated with differential contamination. CSI-
Microbes performs two tests for the identification of cell-type specific intracellular 
microbes: (a) differential abundance, which compares the abundance of the microbial 
taxa between cell types, and (b) differential presence, which compares the percentage 
of cells with at least one read from the microbial taxa between cell types. We use the 
differential presence test for sparsely populated 10x scRNA-seq datasets with few 
microbial reads and the differential abundance test, otherwise.  The output is a list of 
candidate cell type-specific intracellular microbial taxa ranked by their differential 





The algorithm proceeds in the following steps (Figure 6 and see Methods for 
a detailed description): (1) scRNA-seq reads are mapped to microbial genomes and 
spike-in transcripts (differential abundant test only) after filtering the host reads. (2) 
For the differential abundance test, microbial reads are normalized across cells using 
spike-in sequences, log-transformed and compared across specified cell types using a 
two-sided Wilcoxon rank-sum test with minimum log fold-change=.5. The statistical 
significance and the area under the receiver operating curve (AUC), which is 
equivalent to the U statistic of the Wilcoxon rank-sum test111, are used to report the 
abundance of the microbial taxa to discriminate between cell types, for each 
microbial taxa. For the differential presence test, microbial read counts are compared 
across specific cell types using a two-sided binomial test and the statistical 
significance and effect size (log2 fold-change) are reported. Both tests are run 
separately for cells given their covariate annotations (plate for Smart-seq2 and sample 
for 10x) and combined using Stouffer’s Z-score method112. (3) Post-hoc tests of 
contamination inspired by the decontam model55 are performed using spike-in reads 
and empty wells if available (Methods). These include two tests, the spike-in and the 
empty wells test. The spike-in test, which is based on the observation that the number 
of reads from contaminating microbes are likely to correlate inversely with the 
sample DNA concentration, calculates the correlation between the spike-in reads and 
the reads of the taxon of interest. The empty wells test, which is based on the 
observation that contaminating sequences are more likely to show up in negative 
controls, compares the presence of microbial taxa between empty and non-empty 






Figure 6: Overview of the CSI-Microbes approach  
The expected input to CSI-Microbes is FASTQ files and metadata. The first step is (1) 
identification: the mapping of reads to human and microbial genomes and optionally spike-
ins; (2) analysis: comparison of number of cells with at least one microbial UMI between 
cell-types (Differential Presence) or comparison of spike-in normalized microbial reads 
between cell-types (Differential Abundance); (3) validation: correlation of microbial reads 
with spike-in reads (Spike-in Test) and comparison between frequency of microbial reads in 
empty wells vs. wells with cells (Empty Wells Test) 
 
 
3.3.2 Validation of CSI-Microbes on Salmonella exposed scRNA-seq datasets 
We first test CSI-Microbes on a “gold-standard” Smart-seq2 dataset that 
sequenced 262 human monocyte-derived dendritic cells (moDCs) that had been 
exposed to either the D23580 strain or the LT2 strain of Salmonella enterica as well 
as 80 control “mock-infected” cells109. The 262 Salmonella exposed cells were further 
labeled as 135 “infected” and 127 “bystander” cells depending on whether the 
presence of live, intracellular Salmonella could be detected using FACS. We 
identified a median of 8,030 reads per cell that mapped to 859 bacterial genera 





genera and found the abundance of all but Salmonella to be highly correlated with the 
number of spike-in reads, suggesting that they are contaminants. We used CSI-
Microbes to identify differentially abundant microbes between the infected and 
bystander cells and found only the taxonomic path from the class 
Gammaproteobacteria (p-value=9e-6, AUC=.66) down to the species Salmonella 
enterica (p-value=1e-8, AUC=.70) (Figure 7A). We did observe false positives when 
comparing cells across plates, illustrating the importance of controlling for the 
sequencing plate (step 2 in CSI-Microbes, Appendix B).  
We next tested CSI-Microbes on a 10x dataset where the authors sequenced 
3,485 human peripheral blood mononuclear cells (PBMCs) that were exposed to 
Salmonella enterica serovar Typhimurium strain SL1344 as well as 3,515 unexposed 
control cells110. Using flow cytometry, the authors determined that ~3% of the 
exposed peripheral blood mononuclear cells (PBMCs), including 90% of the 
monocytes, were infected with live red fluorescent protein (RFP)-expressing 
intracellular Salmonella. We applied CSI-Microbes to look for differentially present 
microbes between the monocytes and non-monocytes, which identified the path from 
the phylum Proteobacteria to the genus Salmonella despite only 29 UMIs that 
mapped to bacterial genomes in this dataset (Figure 7B).  
Although we do not find a significant difference between the percentage of 
genera-resolved bacterial reads belonging to Salmonella between the two datasets 
(8/27 vs. 756,284/1,643,696 Fisher Exact Test p-value=.12), we do observe 
significantly more microbial reads per cell in the Smart-seq2 dataset compared to the 





for filtering and false discovery correction for 10x vs Smart-seq2 datasets: For 10x 
datasets, we filter microbes that are not present above a minimum threshold of 1% in 
any cell-type, which filters all microbial taxa not belonging to Salmonella in the 
dataset from Bossel Ben-Moshe et al.110 For Smart-seq2 datasets, we filter microbial 
taxa that have fewer than 10 counts per million microbial reads in at least 50% of the 
cells in any cell-type. We control for false discovery rate using hierarchical FDR, 
which leverages the ability of CSI-Microbes to identify differentially abundant taxa 
starting at the class taxonomic level in the NCBI Taxonomy and we report the highest 
resolution, statistically significant microbial taxa (Methods)113,114. We validated our 
findings of differential abundance and differential presence in the Salmonella datasets 
using direct mapping to the respective strain genomes using the error-tolerant aligner 







Figure 7: Results from CSI-Microbes on human cells exposed to Salmonella 
(A) Overview of the results from running CSI-Microbes on the dataset from Aulicino et al.109. 
The first plot is a volcano plot where all microbes were plotting according to the output of the 
differential abundance test (p-value and AUC). The second plot shows the taxonomic 
ordering of the differentially abundant microbes. The third panel shows the abundance of 
Salmonella enterica from infected, bystander and control cells. (B) Output of CSI-Microbes 
on the dataset from sample GSM3454529 from Bossel Ben-Moshe et al.110 The first plot 
shows the output of the differential presence test (the taxonomic ancestors of Mycoplasma 
wenyonii received identical scores and were excluded for space purposes). The second plot 
shows the taxonomic ordering of the differentially present microbes. The third panel shows 
the frequency of the presence of Salmonella in monocytes and non-monocytes. 
 
3.3.3 Application of CSI-Microbes to Merkel cell and colon carcinomas 
We further validate CSI-Microbes by analyzing two 10x scRNA-seq datasets 
from two tumor types that have previously been reported to have tumor cell-specific 





microbes between tumor and non-tumor cells from two Merkel cell tumors, which are 
among the ~80% of these cancers that are driven by the clonal integration of the 
Merkel polyomavirus52,116. In both patients, CSI-Microbes identifies the species 
Human polyomavirus 5, for which the only fully sequenced genome comes from the 
“no rank” child taxon Merkel polyomavirus, to be differentially present in tumor cells 
(patient 2586-4: p-value=6e-5, LFC=2.4; patient 9245-3: p-value=3e-36, LFC=2.4).  
Next, we applied CSI-Microbes to identify differentially present microbes 
between tumor and non-tumor cells from colorectal carcinomas, following previous 
reports that the bacterial species Fusobacterium nucleatum preferentially exists 
within colorectal carcinoma cells and to a lesser extent, stromal cells47,117. In 
agreement with these reports, CSI-Microbes identifies the genus Fusobacterium to be 
differentially present in the tumor cells from patient SC028 (Figure 8A). CSI-
Microbes also identifies the differential presence of the bacterial species Hathewaya 
histolytica (previously called Clostridium histolyticum) in tumor cells of patient 
SC019 and with a trend towards enrichment in the tumor cells from patient SC030 (p-
value=.24, LFC=2.33) (p-value=.009, Figure 8B). This species have been previously 
reported  to be strongly enriched in the colonic tissue of patients with ulcerative 







Figure 8: Results from CSI-Microbes on colorectal carcinoma  
(A) Output of the differential presence test of CSI-Microbes between the tumor and non-
tumor cells from patient SC028 (non-significant ancestors are excluded for space reasons). 
The differentially present microbes and their children are ordered using the NCBI taxonomy. 
The percentage of cells with reads from Fusobacterium nucleatum are show between tumor 
and non-tumor cells (B) Output of the differential presence test of CSI-Microbes between the 
tumor and non-tumor cells from patient SC019. The differentially present microbes are 
ordered using the NCBI taxonomy. The percentage of cells with reads from Hathewaya 
histolytica are show between tumor and non-tumor cells 
3.3.4 Application of CSI-Microbes to lung cancer 
Next, we applied CSI-Microbes to identify differential abundant microbes 
from a large, recently published lung cancer Smart-seq2 scRNA-seq dataset with 
spike-in sequences119. We analyze 13 lung cancer tumors where at least 10 tumor 
cells and 10 non-tumor cells were sequenced in the same plate, comprising in total 





(tumor, immune, stroma and epithelial), we identify multiple tumors where microbial 
taxa are differentially abundant in tumor cells compared to immune cells (TH231, 
TH236, TH238, TH266, see examples in Figure 9A and 9B) and stromal cells 
(TH236, TH266). We also detect two tumors with taxa that are differentially 
abundant in stromal cells (TH231) or immune cells (TH220) compared to tumor cells. 
All four tumor samples containing tumor cells enriched with bacterial taxa are from 
tumors that had undergone at most one prior drug treatment. In contrast, the tumor 
sample with bacterial taxa enriched in immune cells came from a patient who had six 
prior lines of treatment including immunotherapy. Finally, comparing the results of 
CSI-Microbes to the results of 16S rRNA sequencing by Nejman et al.102 in the lung, 
we find at least one unambiguous read to 16 of the 17 species found enriched in lung 
cancer by Nejman et al.102, suggesting that scRNA-seq data may provide sufficient 
coverage of the tumor microbiome.  
CSI-Microbes identifies the species Cutibacterium acnes to be differentially 
abundant in the tumor cells compared to the immune cells in four tumors (TH231, 
TH236, TH238, TH266). Cutibacterium acnes was excluded from a previous 
experimental exploration of the lung tumor microbiome by Nejman et al.102 because it 
was identified in a large percentage of the negative controls, which indicated that it 
may be a contaminant. Consistent with this finding, we identify reads from C. acnes 
in nearly every single cell analyzed. However, C. acnes is significantly more 
abundant in tumor cells compared to immune cells in all four tumors (and is not 
significantly more abundant in non-tumor cells in any other tumor). Notably, C. acnes 





exist intracellularly in epithelial cells120,121. Thus, unlike bulk expression based 
computational methods, CSI-Microbes can consider all microbes while implicitly 
controlling for contaminants by comparing between cells of the same patient. CSI-
Microbes identifies another member of the Cutibacterium genus, Cutibacterium 
granulosum as differentially abundant in tumor cells in patient TH266 (uncorrected p-
value = .04, Figure 8B). Additional genera that are differentially abundant in tumor 
cells include the genera Corynebacterium (TH236 and TH238) and Staphylococcus 
(TH236) and the family Micrococcaceae (TH238) (Figure 8A). In patient TH231, 
where CSI-Microbes found C. acnes to be enriched in tumor cells, it also identified 
the genus Leptotrichia to be enriched in stroma cells compared to other cells. In 
patient TH220, CSI-Microbes identifies both the Micrococcus and Corynebacterium 
genera to be enriched in immune cells compared to tumor cells in patient TH220. We 
do not find any bacterial taxa to be differentially abundant between 






Figure 9: Results from CSI-Microbes on lung cancer 
(A) Overview of the differentially abundant microbes between the tumor and immune cells in 
patient TH238 including a volcano plot, the taxonomical relationship and the abundance of 
specific microbial taxa.  (B) Overview of the differentially abundant microbes including both 
Cutibacterium acnes and Cutibacterium granulosum between the tumor and immune cells in 
patient TH266. (C) Overview of the differentially abundant microbes between the stroma and 
non-stroma cells in patient TH231 including the volcano plot and the taxonomic relationship 
as well as the abundance of genus Leptotrichia across the four major cell types in plate 
B003119 (the only plate from TH231 containing > 1 stroma cell) 
 
 
To study the transcriptomic state associated with the presence of intracellular 





from patients TH231, TH236, TH238 and TH266 (termed “infected” because CSI-
Microbes identified microbial taxa that are differentially abundant in tumor cells in 
each of these samples) and the tumor cells from the other patients (termed 
“uninfected”) (Figure 10A, Methods). At the gene level, the gene most down-
regulated in infected tumor cells compared to uninfected tumors cells is S100A9 
(FDR-corrected p-value=1e-62, AUC=.09), which forms a heterodimer calprotectin 
with S100A8. Calprotectin has antimicrobial properties because of its ability to 
sequester metal ions such as zinc, manganese and iron that are essential nutrients for 
microbes122. The strong down-regulation of calprotectin as well as multiple other 
S100 calcium-binding proteins may explain how bacteria such as C. acnes can 
survive inside tumor cells.  
Next, we performed a gene set enrichment analysis (GSEA) of the 
differentially expressed genes between the “infected” and uninfected cancer cells and 
clustered similar gene sets using Enrichment Map 123 (Figure 10B, Methods). The 
largest cluster of gene sets downregulated in infected tumor cells contains mostly 
gene sets associated with processing and presentation of antigens as well as gene sets 
associated with hematopoietic differentiation and response to external stimulus. This 
cluster is connected to the chemotaxis cluster, which includes gene sets associated 
with chemotaxis of leukocytes, granulocytes and neutrophils. Of note, there are at 
least three additional and unconnected downregulated gene sets involved in anti-
microbial response, including humoral immune response mediated by antimicrobial 
peptides, transition metal ion homeostasis and cell killing. Additionally, multiple 





as well as interleukin-12 production are strongly downregulated in the infected tumor 
vs uninfected cells. The largest cluster of up-regulated gene sets includes many gene 
sets associated with microtubules, which have previously been shown to be 
modulated by intracellular pathogens 124. The association of intracellular bacteria with 
the down regulation of the antigen presentation system in tumor cells, which both we 
(Appendix B) and Aulicino et al.109 observe in the Salmonella dataset, is particularly 
relevant given the recent finding that peptides derived from bacteria can be present on 
the HLA class I and II molecules in melanoma103.  
 
 
Figure 10: Transcriptomic changes between infected and uninfected tumor cells 
(A) Volcano plot of the differentially expressed genes between the infected and uninfected 
tumors cells. (B) Enrichment map of the enriched gene sets (FDR q-value < .02) where nodes 
represent gene sets and edges connect gene sets that share a high number of genes. Similar 
gene sets are clustered and manually named using common terms. 
 
3.4 Discussion 
This paper introduces a new approach for the de novo identification of cell 
type-specific intracellular microbes from scRNA-seq data. We first demonstrate that 





cells analyzing both 10x and Smart-seq2 scRNA-seq datasets and correctly identify 
the infective species. Next, we apply it to analyze scRNA-seq datasets from three 
different cancer types, showing that it identifies cell-type specific intracellular 
bacteria that have been previously reported in the literature, and additionally finds 
sequence evidence for the cell-type specific presence of other intracellular microbes, 
predominately in tumor cells but also in stromal and immune cells. 
One limitation of this paper is that the commonly used scRNA-seq protocols 
that we analyze use polyA tail selection to enrich for polyadenylated eukaryotic 
mRNAs, which selects against prokaryotic RNA molecules, which are less likely to 
be polyadenylated and have shorter polyA tails125. Despite this under sampling, our 
computational approach finds clear evidence of the presence of bacterial reads in 
tumors in a cell-type specific manner. These findings call for further experimental 
testing and validation, e.g., using RNAscope126 to learn how these genomic findings 
correlate with other means of detecting the presence of the microbes in cells. The 
recent findings of intracellular bacteria within tumor cells102,103 obviously raises 
questions concerning the putative functional roles of these intracellular microbes: are 
they simply “innocent bystanders” and opportunistic pathogens or do they play 
important functional roles in tumorigenesis and response to treatment? Our findings 
that moDCs infected with intracellular Salmonella downregulate their antigen 
processing as already suggested by Aulicino et al.109 point to a potential win-win 
relationship between intracellular bacteria and the tumors that host them, in which 





presentation system of the host cell and supports tumor evasion of the immune 
system. 
Finally, we note that CSI-Microbes can be applied to analyze any scRNA-seq 
dataset with multiple cell-types. In such future applications, our results underscore the 
importance of using spike-in sequences, empty wells and multiple cell-types in the 
same plate to further enhance the detection accuracy of intracellular bacteria from 
sequencing data. 
3.5 Methods 
3.5.1 Code and Data Availability 
We analyzed publicly available FASTQ files from the following datasets: 
scRNA-seq of monocyte-derived dendritic 
cells (MoDCs) exposed to Salmonella 
(Smart-seq2)109 
BioProject PRJNA437328 
scRNA-seq of PBMCs exposed to 
Salmonella (10x)110 
BioProject PRJNA503437 
scRNA-seq of Merkel cell carcinoma 
tumors (10x)116 
BioProject PRJNA483959 (patient 
2586-4), PRJNA484204 (patient 
9245-3) 
scRNA-seq of colorectal carcinoma tumors 
(10x)117 
ArrayExpress E-MTAB-8410 




The code is logically partitioned into two modules, one module for the 
“identification” step and one module for the “analysis” step. A reproducible 
Snakemake workflow for identifying microbial reads from scRNA-seq datasets, 
which includes the step of downloading the data from the datasets above, is available 





note that the identification module has some dependencies to the NIH Biowulf server. 
To facilitate reproduction of our analyses, we have uploaded the relevant microbial 
read abundance files to Zenodo. Using these files, the key results from this 
manuscript can be reproduced using a Snakemake workflow focused on the analysis 
module and available on GitHub (https://github.com/ruppinlab/CSI-Microbes-
analysis).  
3.5.2 Preprocessing Steps 
3.5.2.1 Smart-seq2 datasets 
Raw FASTQ files were trimmed using fastp v0.20.1 with the arguments “--
unqualified_percent_limit 40 --cut_tail --low_complexity_filter --trim_poly_x”127. The 
trimmed FASTQ files were aligned to the reference human genome (GRCh38 
gencode release 34) and any applicable spike-in sequences using STAR 
2.7.6a_patch_2020-11-16 with the arguments “--soloType SmartSeq --soloUMIdedup 
Exact --soloStrand Unstranded --outSAMunmapped Within”128.  
3.5.2.2 10x datasets 
Raw FASTQ files were aligned to the reference human genome using 
CellRanger v5.0.1 17 (https://support.10xgenomics.com/single-cell-gene-
expression/software/pipelines/latest/what-is-cell-ranger). The annotated polyA and 
template sequence oligonucleotide (TSO) sequences were trimmed, the unmapped 
reads were converted to the FASTQ file format trimmed and filtered using FASTP as 





3.5.3 Alignment of unmapped reads to microbial genomes 
The unaligned reads were assigned to microbial genomes using PathSeq 
v4.1.8.1 with the arguments “--filter-duplicates false --min-score-identity .7”54. We 
constructed the reference microbial genome database by downloading the set of 
complete viral, bacterial and fungal genomes from RefSeq release 201129. We 
subsampled at least one genome from each species including any genomes annotated 
as either “reference genome” or “representative genome” as well as the genomes of 
the three Salmonella strains used in the “gold-standard” experiments. To mitigate 
vector contamination, we identified regions of suspected vector contamination 
(including “weak” matches) in the genomes using Vecscreen_plus_taxonomy  
(https://github.com/aaschaffer/vecscreen_plus_taxonomy) with the UniVec Database 
(ftp://ftp.ncbi.nlm.nih.gov/pub/UniVec/.) and filtered any reads that aligned to these 
regions130.  
3.5.4 Differential Abundance Quantification 
We define the abundance of a particular microbe in each cell to be the number 
of unambiguous reads assigned to the relevant genome(s) by PathSeq 
(http://software.broadinstitute.org/pathseq/). The abundances are normalized using 
the computeSpikeFactors function from scran v1.16.0, which computes the library 
size factors using the sum of the spike-in sequences131. To limit the number of 
hypotheses, we only test microbial taxa with counts per million microbial reads > 10 
in at least 50% of the cells from a cell-type. The normalized log abundances are 
compared across cell-types using the findMarkers function from scran v1.16.0 with 





value (“direction=’any’”) when lfc > 0 is less unintuitively less conservative than the 
one-sided p-value (either “direction=’up’” or “direction=’down’”) 
(https://github.com/MarioniLab/scran/issues/86) so we ran the comparison twice, 
once using with “direction=’up’” and once with “direction=’down’”, selected the 
result with the smaller p-value for each microbial taxa and converted the one-sided p-
value to the two-sided p-value by taking the minimum of 1 and 2*p-value as 
suggested on p.79 by Sokal and Rohlf132. 
3.5.5 False Discovery Rate Correction 
We use two different approaches for correcting p-values for multiple 
hypotheses. For the CSI-Microbes results from the Salmonella dataset, we run CSI-
Microbes separately for each taxonomic level and correct for the number of OTUs 
tested at that taxonomic level using the Benjamini-Hochberg procedure 82. For the 
CSI-Microbes results from the cancer datasets, we leverage the finding from the 
Salmonella dataset that CSI-Microbes can detect differentially abundant classes. For 
each class, we construct the taxonomic tree using RefSeq v201 and calculate the FDR 
for members of that class using the hFDR.adjust function from the structSSI 
package133 which implements the “outer-nodes” method of Yuketeli113, which is the 
method in that theoretical paper that is best suited for testing parent-child taxa in a 
taxonomic tree. To account for the multiple class hypotheses, we multiply the class-
specific hFDR by the number of classes analyzed by CSI-Microbes to give the overall 
hierarchical FDR (hFDR). We compared the hFDR approach described above with 
FDR correction at the species level for the differential abundance of Salmonella 





reports a more significant FDR-corrected p-value than the species-corrected FDR 
approach (1.58e-8 vs. 2.54e-8).  
3.5.6 Normalization Model 
We extend the model used by decontam to include host and spike-in 
sequences such that we let the total sample RNA (T) be a mixture of 3 components: 
human RNA (H), spike-in RNA (S) and microbial RNA (M)55. We can further divide 
the microbial RNA into contaminating microbial RNA (cM) and true microbial RNA 
(tM). One previously observed pattern of contaminants is the frequency of 
contaminating microbial RNA (cM) is likely to be inversely correlated with the 
human RNA concentration55. We note that the frequency of spike-in RNA is also 
likely to be inversely correlated with the human RNA concentration and therefore the 
frequency of spike-in RNA should be correlated with the frequency of contaminant 
RNA. Therefore, spike-in based normalization should remove any differences in the 
frequency of contaminating sequences between cells.  
3.5.7 Comparison to 16S Tumor Microbiome Findings 
We compared our findings of presence of bacterial taxa as numerical 
identifiers in NCBI’s Taxonomy tree114 to the findings of Nejman et al.102. To do this 
comparison, we had to i) map the findings of Nejman et al.102 to numerical taxa and 
to assess which of the taxa they found are in our reference database. One of the key 
advantages of their 16S method is that it can find taxa for which there is no complete 
genome. In principle, CSI-Microbes can also use sub-genomic sequences in the 





In Nejman et al.102, microbial species were presented by name, which can lead 
to ambiguities because there are many synonyms and the preferred genus-species 
name may change over time. We were able to identify NCBI Taxonomy IDs for 1,783 
of the species identified by Nejman et al.102 739 of these 1,783 species have at least 
one completely sequenced genome and were included in our microbial database. 
These species included 17 lung-cancer matches from Nejman et al.102 
3.5.8 Gene Set Enrichment Analysis 
To perform GSEA between the infected and uninfected tumor cells, we first 
performed differential expression analysis as describe above except that we used 
LFC=0 to limit the number of genes with p-value=1 and thereby the number of tied 
genes. Next, we ranked genes by multiplying the -log10(p-value) by -1 (AUC > 0.50 
for Wilcoxon rank sum test) or 1 (AUC ≤ .50). Finally, we performed gene set 
enrichment analysis using the ranked genes list and the GSEAPreranked function of 
the GSEA tool v4.1.0 with default settings and seed=149134 with the gene ontology 
biological processes gene set from the molecular signature database (MSigDB) v7.3 
134–137. We visualized the enriched gene sets (FDR q-value < .02) using Enrichment 






Chapter 4: Conclusions 
“If the 20th century was the century of physics, the 21st century will be the century of 
biology” 
- Craig J. Venter and Daniel Cohen  
 
If the 21st century is the century of biology (and early indications are positive), 
then there will have to be a significant amount of computational innovation. The 
ability to generate large amounts of more and more sophisticated biological data will 
only continue to grow but this data will only lead to biological discoveries if it can be 
properly analyzed. In this thesis, I present two very different computational 
approaches for the analysis of NGS data that illustrate two different types of 
computational innovations for the analysis of biological data.  
For TCSM, which was my first project, we applied a novel approach (borrowed 
from the field of topic modeling) to the well-studied problem of mutation signature 
extraction and were able to mainly rely on pre-processed data. For my second project, 
CSI-Microbes, we applied a novel approach to the under-studied question of the 
identification of intracellular microbes. To the best of our knowledge, CSI-Microbes 
is the first and only approach to use NGS to try to identify intracellular microbes. Our 
approach uses scRNA-seq data, which is a relatively new technology (in comparison 
to DNA sequencing). This project required both the software engineering ability to 
build scalable, efficient and reproducible pipelines to mine the raw reads of hundreds 





ability to develop proper approaches for normalizing extremely sparse microbial 
reads between single cells.  
Importantly, both of these research projects were computational methods 
motivated by biological observations by myself and my co-authors. In particular, we 
were only able to identify the research question behind CSI-Microbes because of my 
collaboration with the Surgery Branch. One of my most important advantages as a 
computational biologist is that I am genuinely interested in learning and 
understanding the underlying biology. This curiosity has allowed me to both apply 
novel computational methods to solve research questions posed by others and pose 


















Appendix A Figure 1: Comparison of the likelihood of held-out samples of TCSM with the 
LST count, TCSM with the HR biallelic covariate (BRCA1, BRCA2, RAD51C) and TCSM 
with the biallelic inactivation of any of seven recurrently inactivated HR genes (ATM, 







Appendix A Figure 2: The cosine similarity of the five signatures extracted TCSM on the 








Appendix A Figure 3: The five signatures extracted by TCSM on the breast cancer dataset 







Appendix A Figure 4: The model selection output for the SomaticSignatures package83 on the 
breast cancer dataset where the red dot is the mean value across ten runs and the crosses 
represent the results of individual runs. 
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Appendix A Figure 5: The log-likelihood performance on held-out tumors of TCSM using a 
single covariate to represent cancer type (Cancer Type) and TCSM using two binary 







Appendix A Figure 6: The cosine similarity of the four signatures extracted TCSM on the 








Appendix A Figure 7: The four signatures extracted TCSM on the combined LUSC-SKCM 
dataset using a single covariate to represent cancer type. 
 
Appendix B 
Comparison of Salmonella-exposed cells between sequencing plates 
Aulicino et al.109 sequenced the infected, bystander and control cells across 
four sequencing plates. To understand the importance of controlling for the 
sequencing plate (step 2 in CSI-Microbes), we generated all 12 possible datasets with 
the infected cells from one plate and the exposed cells from another. Next, we ran 
CSI-Microbes to identify differentially abundant microbes between the infected and 
bystander cells (without controlling for plate) and it reported at least one genus other 





Direct Mapping to Salmonella genomes using SRPRISM 
We mapped the non-human reads from Aulicino et al.109 against the genomes  
of the Salmonella strains used in each study applying SRPRISM115 to estimate the 
number of Salmonella reads present in the dataset (RefSeq release 201)129. We found 
reads that mapped to the genome of the respective Salmonella strains in all the 
infected and bystander cells as well as the control cells. Similar to the results from 
CSI-Microbes, we found significantly more mapped reads in the infected cells 
compared to both the bystander (two-sided Wilcoxon rank sum test p-value=2e-11) 
and other, mock-infected cells (p-value<2e-16) (Appendix B Figure 1A). Of the 
mapped bacterial reads, ~78% mapped to regions encoding rRNAs (including ~9% 
that mapped to the 7 16S rRNA genes present in each strain), while ~20% mapped to 
regions encoding proteins (Appendix B Direct Mapping Approach). The differential 
abundance between infected and bystander cells patterns was observed more strongly 
for reads mapped to encoding proteins (p-value=6e-14) (Appendix B Figure 1B) than 
for reads mapped to regions encoding rRNA (p-value=3e-9) (Appendix B Direct 
Mapping Approach). 
Next, we applied a similar approach to the dataset from Bossel Ben-Moshe et 
al.110 From the exposed cells, we identified 351 reads that mapped to the SL1344 
genome but the vast majority of these reads either lacked a valid cell barcode or had 
cell barcodes excluded by the original authors. In total, we identified 17 unique 
molecular identifiers (UMIs) from 15 cells expressing intracellular Salmonella. These 





value=.002, odds ration=9.75) (Appendix B Figure 1C) in keeping with the 
experimental findings of Bossel Ben-Moshe et al.110 
Identification of host-transcriptomic changes associated with intracellular 
Salmonella 
We analyzed whether we identify host cell transcriptomic changes associated 
with Salmonella infection in the cells from Aulicino et al. 109. We find 318 human 
genes whose expression is significantly correlated with the abundance of the 
Salmonella genera (Spearman rank correlation FDR < .05). Repeating this analysis 
using the abundance of the other thirty-three most abundant bacterial genera, we find 
that the abundance of only three bacteria genera is correlated with the expression of a 
small number of human genes that mostly encode human ribosomal proteins. 
Reassuringly, we observed a strong correlation between the human genes ranked by 
their differential expression between the infected and bystander cells and ranked by 
their correlation with Salmonella abundance (Spearman rank correlation rho=.59, p-
value=0). A gene set enrichment analysis (GSEA) of the human genes ranked by their 
correlation with Salmonella abundance identified antigen processing and 
presentation of endogenous antigen to be the most strongly down-regulated by 
infection by Salmonella (FDR q-value=7e4, NES=-2.25), which mirrors the original 
findings of Aulicino et al.109 Notably, we find that the expression of the antigen 
presentation genes CD83 and CD40 (already noted by the original authors) is 
negatively correlated with the expression of the Salmonella str. D23580 acid shock 
protein gene D5R57_RS08090 (Spearman correlation rho=-26, FDR=.02 (CD40); 






Appendix B Figure 1: (A) Number of reads per cell mapped to the Salmonella D23580 strain 
genome grouped by cell status from Aulicino2018. (B) Number of reads per cell mapped to 
the protein coding regions of the Salmonella D23580 strain genome grouped by cell status 
from Aulicino2018. (C) The percentage of cells with >= 1 UMI mapped to the Salmonella 
SL1344 strain genome grouped by cell-type from Ben-Moshe2019. 
 
Direct Mapping Approach 
We used SRPRISM (https://github.com/ncbi/SRPRISM) with the default 
parameters115 to map the unaligned reads from Bossel Ben-Moshe et al.110 against the 
genome of Salmonella enterica subspecies enterica serovar Typhimurium strain 
SL1344 (RefSeq assembly accession: GCF_000210855.2)139 and the unaligned reads 
from Aulicino et al.109 against the Salmonella enterica subspecies enterica serovar 
Typhimurium strain LT2 (RefSeq assembly accession: GCF_000006945.2) 140 and 
strain D23580 (RefSeq assembly accession: GCF_900538085.1)141 because it is more 
tolerant of errors than other more commonly used read alignment tools. We assigned 
reads to genes for the Smart-seq2 dataset using the intersect command of bedtools142 
and the gene feature format (GFF) file associated with the RefSeq assembly 





protein coding (gene_biotype=protein_coding) or encoding ribosomal RNA 
(gene_biotype=rRNA).  
Gene Set Enrichment Analysis 
We performed gene set enrichment analysis using the GSEAPreranked 
function of the GSEA tool v4.1.0 with default settings and seed=149134 with the gene 
ontology (GO) biological processes v7.3 gene set from MSigDB134–137. To perform 
GSEA on the Salmonella dataset, we first calculated the Spearman rank correlation 
between the spike-in normalized abundance of the Salmonella genus and the spike-in 
normalized expression of human genes expressed above 10 counts per million (CPM) 
in at least 50% of the cells using the correlatePairs function from scran131. Next, we 
ranked genes by multiplying the -log10(p-value) by -1 (Spearman rank correlation rho 
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